Drug Profile
Research programme: small molecule therapeutics - Bionaut Pharmaceuticals
Alternative Names: BNC-1; BNC-2; BNC-3; BNC-4; BNI-01Latest Information Update: 03 Feb 2011
Price :
$50
*
At a glance
- Originator Bionaut Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation; Macular degeneration
Most Recent Events
- 11 Oct 2005 Compounds from this programme are available for licensing (http://www.bionautpharma.com)
- 11 Oct 2005 Preclinical trials in Inflammation in USA (unspecified route)
- 11 Oct 2005 Preclinical trials in Macular degeneration in USA (unspecified route)